Lipoprotein(a): Structural implications for pathophysiology

International Journal of Clinical and Laboratory Research

Volumn 27, Issue 1, 1997, Pages 14-23

  Koschinsky, M L ^a   Marcovina, S M ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apolipoprotein(a); Atherosclerosis; Lipoprotein(a); Thrombosis

Indexed keywords

ERINACEIDAE; PRIMATES;

EID: 0030835496     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02827238     Document Type: Article

References (94)

1. Durrington PN. Lipoprotein(a) Baillieres Clin Endocrinol Metab 1995; 9:773.
2. Marcovina SM, Levine DM, Lippi G. Lipoprotein(a): structure, measurement, and clinical significance. In: Rifai N, Warnick R, eds. Laboratory measurement of lipids, lipoproteins, and apolipoproteins. Washington, DC: AACC Press; 1994:235.
3. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132.
4. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ. Beisiegel V. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9:579.
5. Marcovina SM, Morrisett JD. Structure and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 136.
6. Koschinsky ML, Ramharack R. Structure, function and regulation of lipoprotein(a). Curr Pharm Design 1996; 2: 121.
7. Albers JJ, Kennedy H, Marcovina SM. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J Lipid Res 1996; 37: 192.
8. Brunner C, Kraft H-G, Utermann G, Muller H-J. Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 1993; 90:11643.
9. 100. J Biol Chem 1993; 268:19819.
10. Hoover-Plow JL, Miles LA, Fless GM, Scanu AM, Plow EF. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen. Biochemistry 1993; 32: 13681.
11. Sangrar W, Marcovina SM, Koschinsky ML. Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells. Protein Eng 1994; 7:723
12. Ernst A, Helmhold M, Brunner C, Petho-Schramm A, Armstrong VW, Muller H-J. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270:6227.
13. Gabel BR, May LR, Marcovina SM, Koschinsky ML. Lipoprotein(a) assembly: quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler Thromb Vasc Biol. In press.
14. Kratzin H, Armstrong VW, Niehaus M, Hilschmann N, Seidel D. Structural relationship of an apolipoprotein(a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. Biol Chem Hoppe Seyler 1987; 368:1533.
15. Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from dissociation of human plasma lipoprotein(a). J Biol Chem 1986; 261:8712.
16. Lo Grasso PV, Cornell-Kennon S, Boettcher BR. Cloning, expression and characterization of human apolipoprotein(a) kringle IV 37. J Biol Chem 1994; 296:21820.
17. Karmansky I, Shnaider H, Palant A, Gruener N. Lysine-binding species of lipoprotein(a) in coronary artery disease. Eur J Clin Invest 1994; 24:360.
18. Bard JM, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra HJ, Fruchart JC. Isolation and characterization of two subspecies of Lp(a). one containing apo E and one free of apo E. Biochim Biophys Acta 1992; 1127:124.
19. 100 in human lipoprotein(a). Chem Phys Lipids 1994; 67/68:35.
20. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiess G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52.
21. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2:933.
22. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: Differential expression of apolipoprotein(a) alleles between American Blacks and Whites. Biochem Biophys Res Commun 1993; 191:1192.
23. Utermann M, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotype: inheritance and relation to Lp(a) lipoprotein concentration in plasma. J Clin Invest 1987; 80:458.
24. Kraft HG, Lingenhel A, Pang RWC, Delport R, Trommsdorff, Vermaak H, Janus ED, Utermann G. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet 1996; 4:74.
25. Marcovina SM, Albers JJ, Wijsman E, Zhang Z-H, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res. In press.
26. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Clausen IC, Faergeman O, Utermann G, Kraft H-G. A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995; 96.150.
27. Mooser V, Mancini FP, Bopp S, Petho-Schramm A, Guerra R, Boerwinkle E, Muller H-J, Hobbs HH. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet 1995; 4:173.
28. Amemiya H, Arinami T, Kikuchi S, Yamakawa-Kobayashi K, Li L, Fujiwara H, Hiroe M, Marumo F, Hamaguchi H. Apolipoprotein(a) size and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis 1996; 123:181.
29. Mancini FP, Mooser V, Guerra R, Hobbs HH. Sequence and microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995; 4:1535.
30. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86:4171.
31. Hegele RA, Sutherland S, Robertson M, Wu L, Emi M, Hopkins PN, Williams RR, Lalouel JM. The effect of genetic determinants of low density lipoprotein levels on lipoprotein(a). Clin Invest Med 1991; 14:146.
32. Averna M, Marcovina SM, Noto D, Cole TG, Krul ES, Schonfeld G. Familial hypobetalipoproteinemia is not associated with low levels of lipoprotein(a). Arterioscler Thromb Vasc Biol 1995; 15:2165.
33. Lindahl G, Mailly F, Humphries S, Seed M. Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolemia: implication for lipoprotein(a) metabolism. Clin Invest 1994; 72:631.
34. Bockxmeer FM van, Mamotte CD, Gibbons FR, Taylor RR. Apolipoprotein epsilon 4 homozygosity - a determinant of restenosis after coronary angioplasty. Atherosclerosis 1994; 110:195.
35. Kraft H-G, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein(a) phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83:137.
36. Steyrer E, Durovic S, Frank S, Giessouf W, Burger A, Dieplinger H, Zechner R, Kostner GM. The role of lecithin: cholesterol acyltransferase for lipoprotein(a) assembly. J Clin Invest 1994; 94:2330
37. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994; 93:2758.
38. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91:443.
39. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990; 85:1542.
40. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB Jr. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95:1403.
41. 2-macroglobulin receptor. FEBS Lett 1993; 325:271.
42. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of chotesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989; 86:5810.
43. Tam SP, Zhang X, Koschinsky ML. Interaction of a recombinant form of apolipoprotein(a) with human fibroblasts and with the human hepatoma cell line HepG2. J Lipid Res 1996; 37:518.
44. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339:301.
45. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments m human urine. J Clin Invest 1996; 97:858
46. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996; 16:905.
47. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315.
48. Dahlen GH, Ericson C, Furberg C. Myocardial infarction and an extra pre-beta lipoprotein fraction. Acta Med Scand 1972; 531:25.
49. Abe A, Noma A, Lee YJ, Yamaguchi H. Studies on apolipoprotein(a) phenotypes. 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery disease. Atherosclerosis 1992; 96:9.
50. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12:1214.
51. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V, Schonitzer D. Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Artenoscler Thromb Vasc Biol 1996; 16:713.
52. Kronenberg F, Kathrein H, Konig P, Neyer U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994; 14:1405.
53. Tyrrell HJ, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 1992; 232:349.
54. Zenker G, Koltringer P, Bone G, Nienderkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17:942.
55. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59:199.
56. Woo J, Lau E, Lam CWK, Kay R, Teoh R, Wong HY, Prall WY, Kreel L, Nicholls MG Hypertension, lipoprotein(a), and apolipoprotein A-1 as risk factors for stroke in the Chinese. Stroke 1991; 22:203.
57. Barbir M, Kushwaha S, Hunt B, Macken A, Thompson GR, Mitchell A, Robinson D, Yacoub M. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 1992; 340:1500.
58. Hoff HF, Beck GJ, Skibinski CI, Jurgers G, O'Neil J, Kramer J. Lytle B. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988; 77:1239.
59. Niendorf A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U, Dietel M. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch [A] 1990; 417:105.
60. Reblin T, Meyer N, Labeur C, Henne-Bruns D, Beisiegel U. Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis 1995; 113:179.
61. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoprotein (a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9:593.
62. Kreuzer J, Lloyd MB, Bok D, Fless GM, Scanu AM, Lusis AJ, Haberland ME Lipoprotein(a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall. Chem Phys Lipids 1994; 67/68:175.
63. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner G. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis 1988; 8:851.
64. Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M. Lipoprotein(a) in the arterial wall. Eur Heart J 1990; 11 [Suppl E]: 174.
65. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein(a) (Lp(a)). Atherosclerosis 1990; 84:173.
66. Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Enholm C. Lipoprotein(a) binds to fibronectin and has serine protease activity capable of cleaving it. EMBO J 1989; 8:4035.
67. Hoek YY van der, Sangrar W, Cote GP, Kastelein JJP, Koschinsky ML. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arterioscler Thromb 1994; 14:1792.
68. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987; 330:113.
69. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 267.4143.
70. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism 1992; 41:1215.
71. Naruszewicz M, Selinter E, Dufour R, Davignon J. Probucol protects lipoprotien(a) against oxidative modification. Metabolism 1992; 41:1225.
72. Bottalico LA, Keesler GA, Fless GM, Tabas I. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem 1993; 268: 8569.
73. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. J Biol Chem 1992; 267:13284.
74. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Siedel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986; 62:249.
75. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274:1771.
76. Gabel BR, Koschinsky ML. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 1995; 34:15777.
77. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995; 34:5151.
78. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Med 1995; 1:256.
79. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86:3847.
80. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240.
81. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339:303.
82. Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32:4628.
83. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. The proliferation of human smooth muscle cells is promoted by lipoprotein(a). Science 1993; 260:1655.
84. Kojima S, Harpel PC, Rifkin DB. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113:1439.
85. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370:460.
86. Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SB, Lembo NJ, Roubin GS, Sgoutas DS. Usefulness of serum apolipoprotien (a) as a predictor of restenosis after percutaneous transluminal coronary angiopiasty. Am J Cardiol 1992; 69:736.
87. Liu AC, Lawn RM. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med 1994; 4:40.
88. Williams JK, Bellinter DA, Nichols TC, Griggs TR, Bumol TF, Fouts RL, Clarkson TB. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb 1993; 13:548.
89. Etingen OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266:2459.
90. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 14:438.
91. Karmansky I, Greener N. Roles of immobilized glycosylated proteins and lipoprotein(a) in adhesivity of endothelial cells: possible implications for atherogenesis. Cell Biol Int Rep 1992; 16:503.
92. Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993; 82:392.
93. Leerink CB, Duif PFCCM, Verhoeven N, Hackeng CM, Leus FR, Prins J, Bouma BN, Rijn HJM van. Apolipoprotein(a) isoform size influences binding of lipoprotein(a) to plasmin-modified des-AA-fibrinogen. Fibrinolysis 1994; 8:214.
94. Leerink CB, Duif PFCCM, Gimpel JA, Kortlandt W, Bouma BN, Rijn HJM van. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost 1992; 68:185.